




Instance: composition-en-94a02a9d12dc7fffcfe59cdd0b624e87
InstanceOf: CompositionUvEpi
Title: "Composition for zavesca Package Leaflet"
Description:  "Composition for zavesca Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/02/238/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp94a02a9d12dc7fffcfe59cdd0b624e87)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - zavesca"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Zavesca is and what it is used for</li>
<li>What you need to know before you take Zavesca</li>
<li>How to take Zavesca</li>
<li>Possible side effects</li>
<li>How to store Zavesca</li>
<li>Contents of the pack and other information</li>
</ol> </div>"""   
          

* section[=].section[+]
  * title =  "1. What zavesca is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What zavesca is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Zavesca contains the active substance miglustat which belongs to a group of medicines that affect 
metabolism. It is used to treat two conditions:</p>
<p>Zavesca is used to treat mild to moderate type 1 Gaucher disease in adults.
In type 1 Gaucher disease, a substance called glucosylceramide is not removed from your body. It 
starts to build up in certain cells of the body s immune system. This can result in liver and spleen 
enlargement, changes in the blood, and bone disease.
The usual treatment for type 1 Gaucher disease is enzyme replacement therapy. Zavesca is only used 
when a patient is considered unsuitable for treatment with enzyme replacement therapy.</p>
<p>Zavesca is also used to treat progressive neurological symptoms in Niemann-Pick type C 
disease in adults and in children.
If you have Niemann-Pick type C disease, fats such as glycosphingolipids build up in the cells of your 
brain. This can result in disturbances in neurological functions such as slow eye movements, balance, 
swallowing, and memory, and in seizures.
Zavesca works by inhibiting the enzyme called  glucosylceramide synthase  which is responsible for 
the first step in the synthesis of most glycosphingolipids.</p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take zavesca"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take zavesca"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2>Do not take Zavesca</h2>
<p>if you are allergic to miglustat or any of the other ingredients of this medicine (listed in section 
6)
Warnings and precautions
Talk to your doctor or pharmacist before taking Zavesca
-
if you suffer from kidney disease
-
if you suffer from liver disease
Your doctor will perform the following tests before treatment and during treatment with Zavesca:
-
an examination to check the nerves in your arms and legs
-
measurement of vitamin B12 levels
-
monitoring growth if you are a child or adolescent with Niemann-Pick type C disease
-
monitoring of blood platelet counts
The reason for these tests is that some patients have had tingling or numbness in the hands and feet, or 
a decrease in body weight, while taking Zavesca. The tests will help the doctor decide whether these 
effects are due to your disease or other existing conditions, or due to side effects of Zavesca (see 
section 4 for further details).
If you have diarrhoea, your doctor may ask you to change your diet to reduce your lactose and 
carbohydrate intake such as sucrose (cane sugar), or not to take Zavesca together with food, or to
temporarily reduce your dose. In some cases the doctor may prescribe anti-diarrhoeal medicines such 
as loperamide. If your diarrhoea does not respond to these measures, or if you have any other 
abdominal complaint, consult your doctor. In such case, your doctor may decide to conduct further 
investigations.
Male patients should use reliable birth control methods during their treatment with Zavesca, and for 
3 months after finishing treatment.
Children and adolescents
Do not give this medicine to children and adolescents (below 18 years old) with type 1 Gaucher 
disease because it is not known if it works in this disease.
Other medicines and Zavesca
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other 
medicines.
Tell your doctor if you are taking medicines containing imiglucerase, which are sometimes used at the 
same time as Zavesca. They may lower the amount of Zavesca in your body.
Pregnancy, breast-feeding and fertility
You should not take Zavesca if you are pregnant or thinking of becoming pregnant. Your doctor can 
give you more information. You must use effective birth control while taking Zavesca. Do not 
breast-feed while you are taking Zavesca.
Male patients should use reliable birth control methods during their treatment with Zavesca, and for 
3 months after finishing treatment.
If you are pregnant, breast feeding, think you may be pregnant or planning to have a baby, ask your 
doctor or pharmacist for advice before taking this medicine.
Driving and using machines
Zavesca may make you feel dizzy. Do not drive or use any tools or machines if you feel dizzy.
Zavesca contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially 
 sodium-free .</p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take zavesca"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take zavesca"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist 
if you are not sure.</p>
<p>For type 1 Gaucher disease: For adults, the usual dose is one capsule (100 mg) three times a 
day (morning, afternoon and evening). This means a daily maximum of three capsules 
(300 mg).</p>
<p>For Niemann-Pick type C disease: For adults and adolescents (over 12 years old), the usual 
dose is two capsules (200 mg) three times a day (morning, afternoon and evening). This means 
a daily maximum of six capsules (600 mg).
For children less than 12 years old, your doctor will adjust the dose for Niemann-Pick type C disease.
If you have a problem with your kidneys you may receive a lower starting dose. Your doctor may 
reduce your dose, e.g., to one capsule (100 mg) once or twice a day, if you suffer from diarrhoea when 
taking Zavesca (see section 4). Your doctor will tell you how long your treatment will last.
To remove the capsule:
1. Separate at perforations
2. Peel back paper at arrows
3. Push product through foil
Zavesca can be taken with or without food. You should swallow the whole capsule with a glass of 
water.
If you take more Zavesca than you should
If you take more capsules than you were told to, consult your doctor immediately. Zavesca has been 
used in clinical trials at doses up to 3000 mg: this caused decreases in white blood cells and other side 
effects similar to those described in section 4. If you forget to take Zavesca
Take the next capsule at the usual time. Do not take a double dose to make up for a forgotten dose.
If you stop taking Zavesca
Don t stop taking Zavesca without talking to your doctor.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p> </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.
Most serious side effects:
Some patients have had tingling or numbness in the hands and feet (seen commonly). They could 
be signs of peripheral neuropathy, due to side effects of Zavesca or they could be due to existing 
conditions. Your doctor will perform some tests before and during treatment with Zavesca to assess 
this (see section 2).
If you do get any of these effects, please seek medical advice from your doctor as soon as 
possible.
If you get a slight tremor, usually trembling hands, seek medical advice from your doctor as soon 
as possible. The tremor often disappears without needing to stop the treatment. Sometimes your doctor 
will need to reduce the dose or stop Zavesca treatment to stop the tremor.
Very common: (may affect more than 1 in 10 people)
The most common side effects are diarrhoea, flatulence (wind), abdominal (stomach) pain, weight loss 
and decreased appetite.
If you do lose some weight when you start treatment with Zavesca don t worry. People usually stop 
losing weight as treatment goes on.
Common: (may affect up to 1 in 10 people)
Common side effects of treatment include headache, dizziness, paraesthesia (tingling or numbness), 
abnormal coordination, hypoaesthesia (reduced sensation to touch), dyspepsia (heartburn), nausea 
(feeling sick), constipation and vomiting, swelling or discomfort in the abdomen (stomach) and 
thrombocytopenia (reduced levels of blood platelets).The neurological symptoms and 
thrombocytopenia could be due to the underlying disease.
Other possible side effects are muscular spasms or weakness, fatigue chills and malaise, depression, 
difficulty sleeping, forgetfulness, and less libido.
Most patients get one or more of these side effects, usually at the start of treatment or at intervals 
during treatment. Most cases are mild and disappear quite quickly. If any of these side effects cause 
problems, consult your doctor. He or she may reduce the dose of Zavesca or recommend other 
medicines to help control side effects.
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side 
effects not listed in this leaflet. You can also report side effects directly via the national reporting 
system listed in Appendix V. By reporting side effects you can help provide more information on the 
safety of this medicine.</p> </div>"""      
        
* section[=].section[+]
  * title = "5. How to store zavesca"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store zavesca"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children.
Do not take this medicine after the expiry date which is stated on the carton after  EXP . The expiry 
date refers to the last day of that month.
Do not store above 30 C.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer take. These measures will help protect the environment.</p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Zavesca contains
The active substance is miglustat 100 mg.
The other ingredients are:
Sodium starch glycollate,
Povidone (K30),
Magnesium stearate.
Gelatin,
Titanium dioxide (E171).
Black iron oxide (E172),
Shellac.
What Zavesca looks like and contents of the pack
Zavesca is a white 100 mg capsule with  OGT 918  printed in black on the cap and  100  printed in 
black on the body.
Box of 4 blister strips, each blister strip containing 21 capsules providing a total of 84 capsules.
Marketing Authorisation Holder:
Janssen-Cilag International NV
Turnhoutseweg B-2340 Beerse
Belgium
Manufacturer:
Janssen Pharmaceutica NV
Turnhoutseweg B-2340 Beerse
Belgium
For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder.
Belgi /Belgique/Belgien
Janssen-Cilag NV
Tel/T l: +32 14 64 94 janssen@jacbe.jnj.com
Lietuva
UAB "JOHNSON &amp; JOHNSON"
Tel: +370 5 278 68 lt@its.jnj.com</p>
<p>&amp;    <br />
 .: +359 2 489 94 jjsafety@its.jnj.com
Luxembourg/Luxemburg
Janssen-Cilag NV
T l/Tel: +32 14 64 94 janssen@jacbe.jnj.com
 esk  republika
Janssen-Cilag s.r.o.
Tel: +420 227 012 Magyarorsz g
Janssen-Cilag Kft.
Tel.: +36 1 884 2janssenhu@its.jnj.com
Danmark
Janssen-Cilag A/S
Tlf: +45 4594 8jacdk@its.jnj.com
Malta
AM MANGION LTD
Tel: +356 2397 6Deutschland
Janssen-Cilag GmbH
Tel: +49 2137 955 jancil@its.jnj.com
Nederland
Janssen-Cilag B.V.
Tel: +31 76 711 1janssen@jacnl.jnj.com
Eesti
UAB "JOHNSON &amp; JOHNSON" Eesti filiaal
Tel: +372 617 7ee@its.jnj.com
Norge
Janssen-Cilag AS
Tlf: +47 24 12 65 jacno@its.jnj.com</p>
<p>Janssen-Cilag    . . . .
T : +30 210 80 90  sterreich
Janssen-Cilag Pharma GmbH
Tel: +43 1 610 Espa a
Janssen-Cilag, S.A.
Tel: +34 91 722 81 contacto@its.jnj.com
Polska
Janssen-Cilag Polska Sp. z o.o.
Tel.: +48 22 237 60 France
Janssen-Cilag
T l: 0 800 25 50 75 / +33 1 55 00 40 medisource@its.jnj.com
Portugal
Janssen-Cilag Farmac utica, Lda.
Tel: +351 214 368 Hrvatska
Johnson &amp; Johnson S.E. d.o.o.
Tel: +385 1 6610 jjsafety@JNJCR.JNJ.com
Rom nia
Johnson &amp; Johnson Rom nia SRL
Tel: +40 21 207 1Ireland
Janssen Sciences Ireland UC
Tel: +353 1 800 709 Slovenija
Johnson &amp; Johnson d.o.o.
Tel: +386 1 401 18 Janssen_safety_slo@its.jnj.com
 sland
Janssen-Cilag AB
c/o Vistor hf.
S mi: +354 535 7janssen@vistor.is
Slovensk  republika
Johnson &amp; Johnson, s.r.o.
Tel: +421 232 408 Italia
Janssen-Cilag SpA
Tel: 800.688.777 / +39 02 2510 1
janssenita@its.jnj.com
Suomi/Finland
Janssen-Cilag Oy
Puh/Tel: +358 207 531 jacfi@its.jnj.com</p>
<p>: +357 22 207 Sverige
Janssen-Cilag AB
Tfn: +46 8 626 50 jacse@its.jnj.com
Latvija
UAB "JOHNSON &amp; JOHNSON" fili le Latvij 
Tel: +371 678 93lv@its.jnj.com
United Kingdom (Northern Ireland)
Janssen Sciences Ireland UC
Tel: +44 1 494 567 This leaflet was last revised in:
Detailed information on this medicine is available on the European Medicines Agency website:
http://www.ema.europa.eu. There are also links to other websites about rare diseases and treatments.</p> </div>"""      



Instance: composition-da-94a02a9d12dc7fffcfe59cdd0b624e87
InstanceOf: CompositionUvEpi
Title: "Composition for zavesca Package Leaflet"
Description:  "Composition for zavesca Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/02/238/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp94a02a9d12dc7fffcfe59cdd0b624e87)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - zavesca"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen
1. Virkning og anvendelse
2. Det skal De vide, før De begynder at tage Zavesca
3. Sådan skal De tage Zavesca
4. Bivirkninger
5. Opbevaring
6. Pakningsstørrelser og yderligere oplysninger</p> </div>"""   
          

* section[=].section[+]
  * title =  "1. What zavesca is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What zavesca is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Zavesca indeholder det aktive stof miglustat, som tilhører en gruppe af lægemidler, som påvirker 
stofskiftet. Det anvendes til behandling af to tilstande:

Zavesca anvendes til behandling af let til moderat Gauchers sygdom, type 1, hos voksne.
Ved Gauchers sygdom, type 1 er der et stof kaldet glucosylceramid, som ikke fjernes fra kroppen. Det 
ophobes i visse celler i kroppens immunsystem. Dette kan medføre forstørrelse af lever og milt, 
forandringer i blodet og knoglesygdom.
Den almindelige behandling af Gauchers sygdom, type 1 er enzymsubstitutionsterapi. Zavesca 
anvendes kun, når en patient anses for uegnet til behandling med enzymsubstitutionsterapi.

Zavesca anvendes også til behandling af fremadskridende neurologiske symptomer ved 
Niemann-Picks sygdom, type C, hos voksne og børn.
Hvis De har Niemann-Picks sygdom, type C, ophobes fedt f.eks. glycosphingolipider i cellerne i Deres 
hjerne. Det kan resultere i forstyrrelser i neurologiske funktioner som f.eks. langsomme
øjenbevægelser, balance, synkning og hukommelse samt i krampeanfald.
Zavesca virker ved at hæmme et enzym, som kaldes ’glucosylceramidsyntase’, som er ansvarlig for det 
første trin i omdannelsen af de fleste glycosphingolipider.</p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take zavesca"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take zavesca"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2>Tag ikke Zavesca</h2>
<p>hvis De er allergisk over for miglustat eller et af de øvrige indholdsstoffer i Zavesca (angivet i 
punkt 6).
21
Advarsler og forsigtighedsregler
Kontakt lægen eller apotekspersonalet, før De tager Zavesca,
-
hvis De lider af en nyresygdom
-
hvis De lider af en leversygdom
Deres læge vil gennemføre følgende tests, før og under behandling med Zavesca:
-
en undersøgelse for at kontrollere nerverne i Deres arme og ben
-
måling af vitamin B12-niveauerne
-
kontrollere Deres vækst, hvis De er barn eller ung med Niemann-Picks sygdom, type C.
-
kontrollere antallet af blodplader
Årsagen til disse prøver er, at visse patients har snurren eller følelsesløshed i hænder og fødder, eller 
taber i vægt, når de tager Zavesca. Prøverne vil hjælpe lægen til at beslutte, om disse virkninger skyldes 
Deres sygdom eller eksisterende tilstande eller er bivirkninger af Zavesca (se punkt 4 for nærmere 
oplysninger).
Hvis De har diarré, vil Deres læge måske bede Dem om følgende: At De ændrer Deres kost for at 
reducere indtagelsen af lactose og kulhydrater såsom sukrose (sukker), at De ikke tager Zavesca 
sammen med måltider, eller at De nedsætter Deres dosis midlertidigt. I nogle tilfælde vil lægen 
ordinere et lægemiddel mod diarré, for eksempel loperamid. Henvend Dem til Deres læge, hvis Deres 
diarré ikke reagerer på disse foranstaltninger, eller hvis De har andre maveproblemer. Hvis det er 
tilfældet vil Deres læge muligvis beslutte, at der skal gennemføres flere undersøgelser.
Mandlige patienter bør anvende pålidelige præventionsmidler under behandling med Zavesca og i 
3 måneder efter, at behandlingen er afsluttet.
Børn og unge
Giv ikke denne medicin til børn og unge (under 18 år) med Gauchers sygdom, type 1, da det ikke vides, 
om den virker.
Brug af anden medicin sammen med Zavesca
Fortæl det altid til lægen eller apotekspersonalet, hvis De tager anden medicin, for nylig har taget anden 
medicin eller planlægger at tage anden medicin. 
Fortæl det til lægen, hvis De tager lægemidler, der indeholder imiglucerase, som nogle gange bruges 
samtidigt med Zavesca. Imiglucerase kan nedsætte mængden af Zavesca i kroppen.
Graviditet, amning og frugtbarhed
De må ikke tage Zavesca, hvis De er gravid, eller hvis De overvejer at blive gravid. Deres læge kan 
give Dem yderligere oplysninger. De skal benytte effektiv prævention, mens De tager Zavesca. De må 
ikke amme, mens De tager Zavesca.
Mænd skal anvende sikker prævention under behandlingen og i 3 måneder efter, behandlingen med 
Zavesca er afsluttet.
Hvis De er gravid eller ammer, har mistanke om, at De er gravid, eller planlægger at blive gravid, skal 
De spørge Deres læge eller apotekspersonalet til råds, før De tager dette lægemiddel.
Trafik- og arbejdssikkerhed
Zavesca kan forårsage svimmelhed. Lad være med at køre bil eller arbejde med værktøj eller maskiner, 
hvis De føler Dem svimmel.
Zavesca indeholder natrium
Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. kapsel, dvs. det er i det 
væsentlige natriumfrit.
22</p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take zavesca"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take zavesca"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er De i tvivl, så spørg lægen eller 
apotekspersonalet.

Ved Gauchers sygdom, type 1: Til voksne er den sædvanlige dosis én kapsel (100 mg) tre 
gange dagligt (morgen, eftermiddag og aften). Det vil sige maksimalt tre kapsler (300 mg) om 
dagen.

Ved Niemann-Picks sygdom, type C: Til voksne og unge (over 12 år) er den sædvanlige dosis 
på to kapsler (200 mg) tre gange dagligt (morgen, eftermiddag og aften). Det vil sige maksimalt 
seks kapsler (600 mg) om dagen.
Lægen vil tilpasse dosis hos børn under 12 år med Niemann-Picks sygdom, type C.
Hvis De har problemer med Deres nyrer, skal De muligvis starte med en lavere dosis. Hvis De lider af 
diarré under behandlingen med Zavesca, vil Deres læge muligvis sætte Deres dosis ned, f.eks. til én 
kapsel (100 mg) én eller to gange dagligt (se punkt 4). Deres læge vil fortælle Dem, hvor længe 
behandlingen skal vare.
Udpakning af kapslen:
1. Adskil ved perforeringerne
2. Træk papiret tilbage ved pilene
3. Tryk produktet gennem folien
Zavesca kan tages sammen med eller uden mad. De skal synke kapslen hel med et glas vand.
Hvis De har taget for meget Zavesca
Hvis De tager flere kapsler, end De har fået besked på, skal De straks søge læge. Zavesca er blevet 
anvendt i kliniske forsøg med doser op til 3 000 mg: Dette medførte et fald i antallet af hvide 
blodlegemer og andre bivirkninger svarende til dem, der er beskrevet i punkt 4. Hvis De har glemt at tage Zavesca
Tag den næste kapsel til sædvanlig tid. De må ikke tage en dobbeltdosis som erstatning for den glemte 
dosis.
Hvis De holder op med at tage Zavesca
Stop ikke med at tage Zavesca uden at rådføre Dem med lægen.
Spørg lægen eller apotekspersonalet, hvis der er noget, De er i tvivl om.</p> </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. 
Mest alvorlige bivirkninger:
Nogle patienter har haft snurren eller følelsesløshed i hænder og fødder (almindelig bivirkning). 
Dette kan være tegn på perifer neuropati, som skyldes bivirkninger af Zavesca, eller det kan være på 
23
grund af eksisterende lidelser. Deres læge vil gennemføre nogle prøver før og under behandling med 
Zavesca for at bedømme dette (se punkt 2).
Hvis De får nogle af disse bivirkninger, skal De søge rådgivning hos lægen så hurtigt som muligt.
Hvis De får en let rysten, sædvanligvis af hænderne, skal De søge rådgivning hos lægen så hurtigt 
som muligt. Denne rysten forsvinder ofte, uden at det er nødvendigt at stoppe behandlingen. Af og til 
vil det være nødvendigt for lægen at nedsætte dosis eller stoppe behandlingen med Zavesca for at 
stoppe denne rysten.
Meget almindelige: (kan forekomme hos flere end 1 ud af 10 behandlede)
De almindeligste bivirkninger er diarré, flatulens (luft i maven), mavesmerter, vægttab og nedsat 
appetit. 
Hvis De taber i vægt, når De starter behandling med Zavesca, skal De ikke blive bekymret. Normalt 
ophører vægttabet ved fortsat behandling.
Almindelige: (kan forekomme hos op til 1 ud af 10 behandlede)
Almindelige bivirkninger af behandlingen omfatter hovedpine, svimmelhed, paræstesi (snurrende 
fornemmelse eller følelsesløshed), koordinationsforstyrrelser, hypoæstesi (nedsat følesans), 
fordøjelsesbesvær (halsbrand), kvalme (utilpashed), forstoppelse og opkastning, hævelse eller ubehag i 
underlivet (maven) og trombocytopeni (nedsat antal blodplader). De neurologiske symptomer og 
trombocytopeni kan skyldes den underliggende sygdom.
Andre mulige bivirkninger er muskelkramper eller -svaghed, træthed, kulderystelser og utilpashed, 
depression, søvnbesvær, glemsomhed og nedsat lyst til sex (libido).
De fleste patienter oplever en eller flere af disse bivirkninger, i reglen i starten af behandlingen eller 
med mellemrum under behandlingen. De fleste tilfælde er lette og forsvinder ret hurtigt. Hvis nogle af 
disse bivirkninger giver anledning til problemer, skal De rådføre Dem med lægen. Han eller hun kan 
nedsætte Deres dosis af Zavesca eller anbefale anden medicin, der kan hjælpe med at kontrollere 
bivirkningerne.
Indberetning af bivirkninger
Hvis De oplever bivirkninger, bør De tale med Deres læge eller apotekspersonalet. Dette gælder 
også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. De eller Deres pårørende kan 
også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan De hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel.</p> </div>"""      
        
* section[=].section[+]
  * title = "5. How to store zavesca"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store zavesca"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn.
Tag ikke lægemidlet efter den udløbsdato, der står på æsken efter EXP. Udløbsdatoen er den sidste dag 
i den nævnte måned.
Må ikke opbevares ved temperaturer over 30 °C.
Spørg apotekspersonalet, hvordan De skal bortskaffe medicinrester. Af hensyn til miljøet må De ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden.</p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Zavesca indeholder:
24
Aktivt stof: miglustat 100 mg.
Øvrige indholdsstoffer:
Natriumstivelsesglycolat, 
Povidon (K30),
Magnesiumstearat.
Gelatine, 
Titandioxid (E171).
Sort Jernoxid (E172),
Shellac.
Udseende og pakningsstørrelser
Zavesca er en hvid 100 mg kapsel med "OGT 918" trykt i sort på kapslens overdel og "100" trykt i sort 
på underdelen.
Æske med 4 blisterpakninger hver indeholdende 21 kapsler, hvilket giver 84 kapsler i alt.
Indehaver af markedsføringstilladelsen:
Janssen-Cilag International NV
Turnhoutseweg 30
B-2340 Beerse
Belgien
Fremstiller:
Janssen Pharmaceutica NV
Turnhoutseweg 30
B-2340 Beerse
Belgien
Hvis De ønsker yderligere oplysninger om dette lægemiddel, skal De henvende Dem til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen:
België/Belgique/Belgien
Janssen-Cilag NV
Tel/Tél: +32 14 64 94 11
janssen@jacbe.jnj.com
Lietuva
UAB "JOHNSON &amp; JOHNSON"
Tel: +370 5 278 68 88
lt@its.jnj.com
България
„Джонсън &amp; Джонсън България" ЕООД
Тел.: +359 2 489 94 00
jjsafety@its.jnj.com
Luxembourg/Luxemburg
Janssen-Cilag NV
Tél/Tel: +32 14 64 94 11
janssen@jacbe.jnj.com
Česká republika
Janssen-Cilag s.r.o.
Tel: +420 227 012 227
Magyarország
Janssen-Cilag Kft.
Tel.: +36 1 884 2858
janssenhu@its.jnj.com
Danmark
Janssen-Cilag A/S
Tlf: +45 4594 8282
jacdk@its.jnj.com
Malta
AM MANGION LTD
Tel: +356 2397 6000
Deutschland
Janssen-Cilag GmbH
Tel: +49 2137 955 955
jancil@its.jnj.com
Nederland
Janssen-Cilag B.V.
Tel: +31 76 711 1111
janssen@jacnl.jnj.com
25
Eesti
UAB "JOHNSON &amp; JOHNSON" Eesti filiaal
Tel: +372 617 7410
ee@its.jnj.com
Norge
Janssen-Cilag AS
Tlf: +47 24 12 65 00
jacno@its.jnj.com
Ελλάδα
Janssen-Cilag Φαρμακευτική Α.Ε.Β.Ε.
Tηλ: +30 210 80 90 000
Österreich
Janssen-Cilag Pharma GmbH
Tel: +43 1 610 300
España
Janssen-Cilag, S.A.
Tel: +34 91 722 81 00
contacto@its.jnj.com
Polska
Janssen-Cilag Polska Sp. z o.o.
Tel.: +48 22 237 60 00
France
Janssen-Cilag
Tél: 0 800 25 50 75 / +33 1 55 00 40 03
medisource@its.jnj.com
Portugal
Janssen-Cilag Farmacêutica, Lda.
Tel: +351 214 368 600
Hrvatska
Johnson &amp; Johnson S.E. d.o.o.
Tel: +385 1 6610 700
jjsafety@JNJCR.JNJ.com
România
Johnson &amp; Johnson România SRL
Tel: +40 21 207 1800
Ireland
Janssen Sciences Ireland UC
Tel: +353 1 800 709 122
Slovenija
Johnson &amp; Johnson d.o.o.
Tel: +386 1 401 18 00
Janssen_safety_slo@its.jnj.com
Ísland
Janssen-Cilag AB
c/o Vistor hf.
Sími: +354 535 7000
janssen@vistor.is
Slovenská republika
Johnson &amp; Johnson, s.r.o.
Tel: +421 232 408 400
Italia
Janssen-Cilag SpA
Tel: 800.688.777 / +39 02 2510 1
janssenita@its.jnj.com
Suomi/Finland
Janssen-Cilag Oy
Puh/Tel: +358 207 531 300
jacfi@its.jnj.com
Κύπρος
Βαρνάβας Χατζηπαναγής Λτδ
Τηλ: +357 22 207 700
Sverige
Janssen-Cilag AB
Tfn: +46 8 626 50 00
jacse@its.jnj.com
Latvija
UAB "JOHNSON &amp; JOHNSON" filiāle Latvijā
Tel: +371 678 93561
lv@its.jnj.com
United Kingdom (Northern Ireland)
Janssen Sciences Ireland UC
Tel: +44 1 494 567 444
Denne indlægsseddel blev senest ændret
De kan finde yderligere oplysninger om Zavesca på Det Europæiske Lægemiddelagenturs hjemmeside: 
http://www.ema.europa.eu. Der er også links til andre websteder om sjældne sygdomme og om,
hvordan de behandles.
26</p> </div>"""      





                    
Instance: bundlepackageleaflet-en-94a02a9d12dc7fffcfe59cdd0b624e87
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for zavesca Package Leaflet for language en"
Description: "ePI document Bundle for zavesca Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-94a02a9d12dc7fffcfe59cdd0b624e87"
* entry[0].resource = composition-en-94a02a9d12dc7fffcfe59cdd0b624e87

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp94a02a9d12dc7fffcfe59cdd0b624e87"
* entry[=].resource = mp94a02a9d12dc7fffcfe59cdd0b624e87
                            
                    
Instance: bundlepackageleaflet-da-94a02a9d12dc7fffcfe59cdd0b624e87
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for zavesca Package Leaflet for language da"
Description: "ePI document Bundle for zavesca Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-94a02a9d12dc7fffcfe59cdd0b624e87"
* entry[0].resource = composition-da-94a02a9d12dc7fffcfe59cdd0b624e87

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp94a02a9d12dc7fffcfe59cdd0b624e87"
* entry[=].resource = mp94a02a9d12dc7fffcfe59cdd0b624e87
                            
                    



Instance: mp94a02a9d12dc7fffcfe59cdd0b624e87
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Zavesca 100 mg capsules"
Description: "Zavesca 100 mg capsules"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/02/238/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Zavesca 100 mg capsules"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 94a02a9d12dc7fffcfe59cdd0b624e87ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "zavesca"

* status = #current
* mode = #working

* title = "List of all ePIs associated with zavesca"

* subject = Reference(mp94a02a9d12dc7fffcfe59cdd0b624e87)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#zavesca "zavesca"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-94a02a9d12dc7fffcfe59cdd0b624e87) // zavesca en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-94a02a9d12dc7fffcfe59cdd0b624e87) // zavesca da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-94a02a9d12dc7fffcfe59cdd0b624e87
InstanceOf: List

* insert 94a02a9d12dc7fffcfe59cdd0b624e87ListRuleset
    